Roche entered into a Licensing, Development, and Commercialisation agreement with Prothena in December 2013 to develop and commercialise monoclonal antibodies targeting aggregated alpha-synuclein, ...

These findings suggest that the combination of olverembatinib and blinatumomab offers promising clinical benefits and an optimal safety profile in patients with Ph+ or Ph-like ALL, thus representing a ...

In the quest for enhanced athletic performance and muscle growth, many fitness enthusiasts and bodybuilders turn to ...